Next Generation Biodegradable Polymer Technology

Sirolimus-eluting stent featuring a biodegradable polymer and a unique micro-porous PEARL surface, favours better endothelialisation and optimal drug delivery. With 10 years of clinical data, it demonstrates improved long-term performance compared to first-generation DES. The stent’s innovative 2-strut connector design ensures maximum flexibility and optimal side branch access, making it ideal for bifurcation stenting

Sirolimus

A clinically proven immunosuppressant, Sirolimus inhibits T and B cell activation via mTOR inhibition, reducing IL-2 sensitivity. Its anti-proliferative properties prevent restenosis when used with coronary stents.

Microporous Surface (PEARL)

The PEARL surface, combined with a biodegradable polymer, enhances endothelialization, reduces restenosis and thrombosis, and ensures controlled drug release, delivering optimal performance as a safe and effective DES technology.

Next-Generation Design

Abluminal Coating

Facilitates unidirectional drug release and less systemic exposure, ensuring improved healing & faster endothelialization.

Clinical Studies

10 Years of Robust Data Setting New Standards Longest-Studied DES Technology ​

In ACS patients, the Yukon stent demonstrated a lower 10-year POCE (65.3% vs. 69% for PP-DES) and a 23% reduced risk of total stent thrombosis.

2021

The ISAR-TEST 4 trial’s 10-year follow-up reported the lowest rate of definite/probable stent thrombosis, showing a 50% risk reduction compared to the Cypher stent and a 29% lower rate compared to Xience.3

2022

At 10 years, Yukon stent outcomes were comparable to Xience in patients with coronary artery disease, including those with Diabetes Mellitus4, with no significant difference in clinical event rates.

2018

3. Circulation, 138, 00-00. DOI: 10.1161/CIRCULATIONAHA.118.038065
4. J Am Heart Assoc. 2021;10e020165 DOI:10.1161/JAHA.120.020165

Type and press enter to search